[1] Segal BH.Aspergillosis[J].N Engl J Med,2009,360(18):1870-1884.
[2] Kontoyiannis DP,Marr KA,Park BJ,et al.Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients,2001-2006:overview of the Transplant-Associated Infection Surveillance Network(TRANSNET) Database[J].Clin Infect Dis,2010,50(8):1091-1100.
[3] Walsh TJ,Anaissie EJ,Denning DW,et al.Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J].Clin Infect Dis,2008,46(3):327-360.
[4] Tsitsikas DA,Morin A,Araf S,et al.Impact of the revised(2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis[J].Med Mycol,2012,50(5):538-542.
[5] Morrissey CO,Chen SC,Sorrell TC,et al.Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients:a randomised controlled trial[J].Lancet Infect Dis,2013,13(6):519-528.
[6] Aguado JM,Vazquez L,Fernandez-Ruiz M,et al.Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients:a randomized controlled trial[J].Clin Infect Dis,2015,60(3):405-414.
[7] Mohammadi S,Khalilzadeh S,Goudarzipour K,et al.Bronchoalveolar galactomannan in invasive pulmonary aspergillosis:a prospective study in pediatric patients[J].Med Mycol,2015,53(7):709-716.
[8] Sadique Z,Grieve R,Harrison DA,et al.An integrated approach to evaluating alternative risk prediction strategies:a case study comparing alternative approaches for preventing invasive fungal disease[J].Value Health,2013,16(8):1111-1122.
[9] Eigl S,Prattes J,Reinwald M,et al.Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test[J].Int J Antimicrob Agents,2015.
[10] Klont RR,Mennink-Kersten MA,Ruegebrink D,et al.Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis[J].Clin Infect Dis,2006,43(3):e23-25.
[11] Ketai L,Jordan K,Busby KH.Imaging infection[J].Clin Chest Med,2015,36(2):197-217,viii.
[12] Kuhlman JE,Fishman EK,Siegelman SS.Invasive pulmonary aspergillosis in acute leukemia:characteristic findings on CT,the CT halo sign,and the role of CT in early diagnosis[J].Radiology,1985,157(3):611-614.
[13] Leeflang MM,Debets-Ossenkopp YJ,Wang J,et al.Galactomannan detection for invasive aspergillosis in immunocompromised patients[J].Cochrane Database Syst Rev,2015,12:doi:10.1002/14651858. |